Abstract
Neurofibromatosis type 1 (NF1) is a complex multisystem disorder with an autosomal dominant pattern of inheritance and marked clinical variability. In the last 15 years, there have been a number of studies which have influenced our current understanding of the frequency and nature of cognitive deficits in NF1. Collectively, the studies reviewed here reveal that cognitive impairment, learning difficulties, and behavioural disturbances such as attention deficit hyperactivity disorder (ADHD) are highly prevalent and undoubtedly reflect a perturbation of central nervous system functioning. Neuroimaging studies have provided important insight into the structural and functional brain abnormalities involved which include alternations in brain organisation for language and visuospatial function and increased total brain volume, with additional areas of interest including the corpus callosum, cerebral asymmetries, thalamus, and striatum. Recent studies in animal models are also beginning to provide insights into the underlying biochemical mechanisms including abnormal activation of the Ras–MAPK pathway and alternations in neurotransmitters such as dopamine and GABA. These studies are vital to the development of targeted treatment for cognitive deficits in NF1.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Acosta MT, Kardel PG, Walsh KS, Rosenbaum KN, Gioia GA, Packer RJ (2011) Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase 1 study. Peadiatr Neurol 45:241–245
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
Baron IS (2004) Neuropsychological evaluation of the child. Oxford University Press, New York
Bawden H, Dooley J, Buckley D, Camfield P, Gordon K, Riding M, Llewellyn G (1996) MRI and nonverbal cognitive deficits in children with neurofibromatosis 1. J Clin Exp Neuropsychol 18:784–792
Billingsley RL, Schrimsher GW, Jackson EF, Slopis JM, Moore B (2002) Significance of planum temporale and planum parietale morphologic features in neurofibromatosis type 1. Arch Neurol 59:616–622
Billingsley RL, Jackson EF, Slopis JM, Swank PR, Mahankali S, Moore BD 3rd (2003a) Functional magnetic resonance imaging of phonologic processing in neurofibromatosis 1. J Child Neurol 18:731–740
Billingsley RL, Slopis JM, Swank PR, Jackson EF, Moore B (2003b) Cortical morphology associated with language function in neurofibromatosis type 1. Brain Lang 85:125–139
Billingsley RL, Jackson EF, Slopis JM, Swank PR, Mahankali S, Moore BD (2004) Functional MRI of visual-spatial processing in neurofibromatosis, type I. Neuropsychologia 42:395–404
Brewer VR, Moore BD 3rd, Hiscock M (1997) Learning disability subtypes in children with neurofibromatosis. J Learn Disabil 30:521–533
Brown JA, Emnett RJ, White CR, Yuede CM, Conyers SB, O’Malley KL, Wozniak DF, Gutmann DH (2010a) Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet 19:4515–4528
Brown JA, Gianino SM, Gutmann DA (2010b) Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci 30:5579–5589
Chabernaud C, Sirinelli D, Barbier C, Cottier J-P, Sembely C, Giraudeau B, Deseille-Turlotte G, Lorette G, Barthez M-A, Castelnau P (2009) Thalamo-striatal T2-weighted hyperintensities (unidentified bright objects) correlate with cognitive impairments in neurofibromatosis type 1 during childhood. Dev Neuropsychol 34:736–748
Clements-Stephens AM, Rimrodt SL, Gaur P, Cutting LE (2008) Visuospatial processing in children with neurofibromatosis type 1. Neuropsychologia 46:690–697
Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415:526–530
Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ (2008) Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:549–560
Cutting LE, Levine TM (2010) Cognitive profile of children with neurofibromatosis and reading disabilities. Child Neuropsychol 16:417–432
Dilts CV, Carey JC, Kircher JC, Hoffman RO, Creel D, Ward K, Clark E, Leonard CO (1996) Children and adolescents with neurofibromatosis 1: a behavioral phenotype. J Dev Behav Pediatr 17:229–239
Dubovsky EC, Booth TN, Vezina G, Samango-Sprouse SA, Palmer KM, Brasseux CO (2001) MR imaging of the corpus callosum in paediatric patients with neurofibromatosis type 1. Am J Neuroradiol 22:190–195
Durston S (2003) A review of the biological bases of ADHD: what have we learned from imaging studies? Mental Retard Dev Disabil Res Rev 9:184–195
Eldridge R, Denckla MB, Bien E, Myers S, Kaiser-Kupfer M, Pikus A, Schlesinger S, Parry D, Dambrosia J, Zasloff M, Mulvihill J (1989) Neurofibromatosis type 1. Am J Dis Child 14:833–837
Eliason MJ (1986) Neurofibromatosis: implications for learning and behavior. J Dev Behav Pediatr 7:175–179
Ferner RE, Chaudhuri R, Bingham J, Cox T, Hughes RA (1993) MRi in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 56:492–495
Ferner RE, Hughes RA, Weinman J (1996) Intellectual impairment in neurofibromatosis 1. J Neurol Sci 138:125–133
Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ (2002) Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc 8:58–71
Goh W, Khong P, Leung C, Wong V (2004) T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: the impact of cognitive function. Neurology 19:853–858
Greenwood RS, Tupler LA, Whitt JK, Buu A, Dombeck CB, Harp AG, Payne ME, Eastwood JE, Krishnan KR, MacFall JR (2005) Brain morphometry, T2-weighted hyperintensities, and IQ in children with neurofibromatosis type 1. Arch Neurol 62:1904–1908
Harnadek MCS, Rourke BP (1994) Principal identifying features of the syndrome of non-verbal learning disabilities in children. J Learn Dis 27:144–154
Hofman KJ, Harris EL, Bryan RN, Denckla MB (1994) Neurofibromatosis type 1: the cognitive phenotype. J Paediatr 124:S1–S8
Huijbregts S, Swaab H, de Sonneville L (2010) Cognitive and motor control in neurofibromatosis type I: influence of maturation and hyperactivity-inattention. Dev Neuropsychol 35:737–751
Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis A clinical and population study in south-east Wales. Brain 111:1355–1381
Hyman SL, Shores A, North K (2005) The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037–1044
Hyman SL, Shores EA, North K (2006) Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 48:973–977
Hyman SL, Gill DS, Shores EA, Steinberg A, North K (2007) T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry 78:1088–1091
Joy P, Roberts C, North K, de Silva M (1995) Neuropsychological function and MRI abnormalities in neurofibromatosis type 1. Dev Med Child Neurol 37:906–914
Kandel ER, Kupferman I, Iverson S (2000) Learning and memory. In: Kandel ER, Schwartz JH, Jessell TM (eds) Principles of neural science. McGraw-Hill, New York
Kayl AE, Moore BD, Slopis JM, Jackson EF, Leeds NE (2000) Quantitative morphology of the corpus callosum in children with neurofibromatosis and attention-deficit hyperactivity disorder. J Child Neurol 15:90–95
Koth CW, Cutting LE, Denckla MB (2000) The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 6:185–194
Legius EM, Descheemaeker MJ, Steyaert J (1995) Neurofibromatosis type 1 in childhood: correlation of MRI findings with intelligence. Neurology 59:638–640
Levine TM, Materek A, Abel J, O’Donnell M, Cutting LE (2006) Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol 13:8–20
Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment, 4th edn. Oxford University Press, New York
Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961–1967
Lorenzo J, Barton B, Acosta MT, North K (2011) Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr 158(4):660–665
Mautner VF, Kluwe L, Thakker SD, Leark RA (2002) Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 44(3):164–170
Mazzocco MMM, Turner JE, Denckla MB, Hofman KJ, Scanlon DC, Vellutino FR (1995) Language and reading deficits associated with neurofibromatosis type 1: evidence for a not-so-nonverbal learning disability. Dev Neuropsychol 11:503–522
Moore BD 3rd, Slopis JM, Schomer D, Jackson EF, Levy BM (1996) Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 46:1660–1668
Moore BD 3rd, Slopis JM, Jackson EF, De Winter AE, Leeds NE (2000) Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 54:914–920
North K (2000) Neurofibromatosis type 1. Am J Med Genet 97:119–127
North K, Joy P, Yuille D, Cocks N, Mobbs E, Hutchins P, McHugh K, de Silva M (1994) Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 44:878–883
North K, Joy P, Yuille D, Cocks N, Hutchins P (1995) Cognitive function and academic performance in children with neurofibromatosis type 1. Dev Med Child Neurol 37:427–436
North K, Riccardi V, Samango-Sprouse C, Ferner R, Moore B, Legius E, Ratner N, Denckla MB (1997) Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 48:1121–1127
Payne JM, Barton B, Shores EA, North KN (2012) Paired associate learning in children with neurofibromatosis type1: implications for clinical trials. J Neurol (Epub ahead of print)
Payne JM, Hyman SL, Shores EA, North K (2011) Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behavior. Child Neuropsychol 17(4):313–329
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948
Pride N, Payne JM, Webster R, Shores EA, Rae C, North K (2010) Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol 25:834–841
Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJS, Huijbregts SCJ (2009) Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychology 23:50–60
Roy A, Roulin JL, Charbonnier V, Allain P, Fasotti L, Barbarot S, Stalder JF, Terrien A, Le Gall D (2010) Executive dysfunction in children with neurofibromatosis type 1. A study of action planning. J Int Neuropsychol Soc 16:1056–1063
Said SM, Yeh TL, Greenwood RS, Whitt JK, Tupler LA, Krishnan KR (1996) MRI morphometric analysis and neuropsychological function in patients with neurofibromatosis. Neuroreport 7(12):1941–1944
Samuelsson B, Axelsson R (1981) Neurofibromatosis. A clinical and genetic study of 96 cases in Gothenburg, Sweden. Acta Derm Venereol Suppl 95:67–71
Sangster J, Shores EA, Watt S, North K (2011) The cognitive profile of preschool-aged children with neurofibromatosis type 1. Child Neuropsychol 17(1):1–16
Schrimsher GW, Billingsley RL, Slopis JM, Moore B (2003) Visual-spatial performance deficits as a diagnostic indicator in children with neurofibromatosis type-1. Am J Med Genet 120A:326–330
Shaywitz SE, Shaywitz BA, Pugh KR, Fulbright RK, Constable RT, Mencl WE, Shankweiler DP, Liberman AM, Skudlarski P, Fletcher JM (1998) Functional disruption in the organisation of the brain for reading in dyslexia. Proc Natl Acad Sci USA 95:2636–2641
Shilyansky C, Karlsgodt KH, Cummings DM, Sidiropoulou K, Hardt M, James AS, Ehninger D, Bearden CE, Poirazi P, Jentsch JD, Cannon TD, Levine MS, Silva AJ (2010a) Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci USA 107:13141–13146
Shilyansky C, Lee YS, Silva AJ (2010b) Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Annu Rev Neurosci 33:221–243
Silva AJ, Frankland PW, Marowitz Z, Friedman E, Laszlo GS, Cioffi D, Jacks T, Bourtchuladze R (1997) A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 15:281–284
Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH (2002) Differential muscarinic and MD contributions to visor-spatial paired-associate learning in rhesus monkeys. Psychopharmacology (Berl) 160:253–262
Thompson HL, Viskochil D, Stevemson DA, Chapman KL (2010) Speech-language characteristics of children with neurofibromatosis type 1. J Med Genet 152A:284–290
Ullrich NJ, Ayr L, Leaffer E, Irons MB, Rey-Casserly C (2010) Pilot study of a novel computerised task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol 2010:1195–1202
Wang PY, Kaufmann WE, Koth CW, Denckla MB, Barker PB (2000) Thalamic involvement in neurofibromatosis type 1: evaluation with proton MR spectroscopic imaging. Ann Neurol 47:477–484
Watt SE, Shores A, North K (2008) An examination of lexical and sublexical reading skills in children with neurofibromatosis type 1. Child Neuropsychol 14:401–418
Zoller ME, Rembeck B, Backman L (1997) Neuropsychological deficits in adults with neurofibromatosis type 1. Acta Neurol Scand 95:225–232
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pride, N.A., North, K.N. (2012). The Cognitive Profile of NF1 Children: Therapeutic Implications. In: Upadhyaya, M., Cooper, D. (eds) Neurofibromatosis Type 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-32864-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-32864-0_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-32863-3
Online ISBN: 978-3-642-32864-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)